APA

Dalgard O., Bjøro K., Ring-Larsen H., Bjornsson E., Holberg-Petersen M., Skovlund E., Reichard O., Myrvang B., Sundelöf B., Ritland S., Hellum K., Frydén A., Florholmen J. & Verbaan H. (20080304). Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. : Hepatology (Baltimore, Md.).

Chicago

Dalgard Olav, Bjøro Kristian, Ring-Larsen Helmer, Bjornsson Einar, Holberg-Petersen Mona, Skovlund Eva, Reichard Olle, Myrvang Bjørn, Sundelöf Bo, Ritland Ståle, Hellum Kjell, Frydén Aril, Florholmen Jon and Verbaan Hans. 20080304. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. : Hepatology (Baltimore, Md.).

Harvard

Dalgard O., Bjøro K., Ring-Larsen H., Bjornsson E., Holberg-Petersen M., Skovlund E., Reichard O., Myrvang B., Sundelöf B., Ritland S., Hellum K., Frydén A., Florholmen J. and Verbaan H. (20080304). Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. : Hepatology (Baltimore, Md.).

MLA

Dalgard Olav, Bjøro Kristian, Ring-Larsen Helmer, Bjornsson Einar, Holberg-Petersen Mona, Skovlund Eva, Reichard Olle, Myrvang Bjørn, Sundelöf Bo, Ritland Ståle, Hellum Kjell, Frydén Aril, Florholmen Jon and Verbaan Hans. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. : Hepatology (Baltimore, Md.). 20080304.